IT 
EN 
DE 
FR 
ES 
PT 
PL 
HU 
EL 
HR 
TR 
NL 
DA 
TH 
JA 
RU 
Earlier this year, Alvin Luk attended the CRISPR Medicine Conference in Copenhagen to provide an update on the HERO clinical trial for MECP2 Duplication Syndrome. Alvin’s presentation is available for the community to watch on YouTube.
In this video, you’ll learn about Huidagene’s experimental CRISPR-Cas13 therapy, HG204, and see the progress in the first treated child, three months after receiving the investigational drug. Skip to minute 26:00 for video footage of the patient.
These early results are very encouraging and further suggest that restoring MeCP2 protein levels could be a promising strategy to tackle MDS.
A second child has already been treated with HG204, and up to six patients are expected to be enrolled sequentially in this trial in China.
